arrow
M

Mark C. Markowski

Johns Hopkins School of Medicine
H指数:30
被引数:2,720

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Muscadine Grape Skin Extract in Biochemically Recurrent Prostate Cancer: A Randomized, Placebo-Controlled, Biomarker-Enriched Trial in Patients With the SOD2 Ala/Ala Variant

蛇皮葡萄提取物在生物化学复发性前列腺癌中的应用:一项针对携带SOD2 Ala/Ala变异患者的随机、安慰剂对照、生物标志物富集试验

2025-05-050
PRE
Inferred clonal hematopoiesis from tumor DNA sequencing among men with prostate cancer: correlation with somatic tumor alterations and outcomes

从前列腺癌患者肿瘤DNA测序中推断出的克隆性造血:与肿瘤体细胞改变及预后的相关性

2025-04-220
OA
Digital Pathology–based Artificial Intelligence Biomarker Validation in Metastatic Prostate Cancer

基于数字病理的 Artificial Intelligence 生物标志物验证在转移性前列腺癌中的应用

2024-12-010
PRE
Phase I/II trial of oral masofaniten (EPI-7386) in combination with enzalutamide (Enz) compared to enz alone in metastatic castration-resistant prostate cancer (mCRPC) subjects

口服masofaniten(EPI-7386)联合enzalutamide(Enz)与单独使用enzalutamide(Enz)治疗转移性去势抵抗性前列腺癌(mCRPC)受试者的I/II期临床试验

2024-09-010
PRE
Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial
2024-01-026
OAAI
MYC-driven increases in mitochondrial DNA copy number occur early and persist throughout prostatic cancer progression

MYC驱动的线粒体DNA拷贝数增加发生在早期,并在整个前列腺癌进展中持续存在

2023-12-220
OA
Predicting Prostate Cancer Molecular Subtype With Deep Learning on Histopathologic Images
2023-10-0111
OAAI
Molecular pathology studies reveal PD1+CD8 T cell density correlates with response to supraphysiological testosterone treatment in pre-treatment biopsies and MYC mRNA and protein correlate with response after treatment
2023-04-040
PRE
Androgen receptor activity in prostate cancer dictates efficacy of bipolar androgen therapy through MYC
2022-12-0127
OAAI